News

Filter News By

Clear Filters

  1. William Skach, Chief Scientific Officer, to Retire From the CF Foundation

    March 31, 2021

    Dr. Skach will retire from the Cystic Fibrosis Foundation this summer.

    Topics:

  2. CF Foundation Awards Contract to Life Edit Therapeutics to Explore Gene Editing Technology in CF

    March 23, 2021

    Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.

  3. CF Foundation Extends Collaboration With Exercise and Wellness Platform Beam Through 2021

    March 9, 2021

    The Cystic Fibrosis Foundation has renewed its commitment to supporting the health and well-being of adults living with cystic fibrosis by supporting free access to the online exercise, education, and well-being platform, Beam.

    Topics:

  4. CF Foundation Reaffirms Support for COVID-19 Vaccination for People Living With Cystic Fibrosis

    March 1, 2021

    FDA issues emergency use authorization for a third COVID-19 vaccine.

  5. CF Foundation Awards Up to $2.17 Million to Beyond Air® to Develop Portable NTM Treatment

    February 16, 2021

    Today, the Cystic Fibrosis Foundation announced that it has awarded up to $2.17 million to Beyond Air® to support the development of a portable inhaled nitric oxide treatment for nontuberculous mycobacteria, difficult-to-treat bacteria that infect the lungs of people with cystic fibrosis.

  6. CF Foundation Has Awarded Up to $3M to Kinnear Pharmaceuticals for Anti-Infective

    January 26, 2021

    The Cystic Fibrosis Foundation has awarded up to $3 million to Kinnear Pharmaceuticals to conduct preclinical testing of a broad-spectrum anti-infective that has the potential to treat multi-drug resistant Pseudomonas and other infections in people with cystic fibrosis.

  7. FDA Accepts Vertex Application for Expansion of Trikafta to Include Children ages 6-11

    January 26, 2021

    Today, Vertex Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has accepted its application to expand Trikafta® (elexacaftor/tezacaftor/ivacaftor) to include children ages 6-11 years old with cystic fibrosis who have at least one F508del or a mutation in the CFTR gene that is responsive based on in vitro data. The FDA has granted priority review of the application and has indicated that it will make a decision by June 8, 2021.

  8. CF Foundation Awards Up to $2M to Eloxx for Additional Support for Studies into Nonsense Mutations Therapy

    January 13, 2021

    Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations.

  9. CF Foundation Strongly Supports COVID-19 Vaccine Recommendations for People Living With Cystic Fibrosis

    January 7, 2021

    On Thursday, January 14 at 7 p.m. ET the CF Foundation will host a live town hall where top questions about the COVID-19 vaccines will be answered by a panel of experts. Register here.

  10. FDA Approves Expansion of Modulators for People With Certain Rare Mutations

    December 21, 2020

    The U.S. Food and Drug Administration today expanded its approval of three CFTR modulators to include additional people with CF who have certain rare mutations. The approval enables more than 600 individuals with CF who were not previously eligible for modulators to access drugs that treat the underlying cause of their disease for the first time.

  11. Cystic Fibrosis Foundation Announces Nine Research Agreements to Advance Its Path to a Cure

    December 10, 2020

    The Cystic Fibrosis Foundation announced a new set of research agreements to drive progress on its Path to a Cure. The nine awards will advance a variety of tools and strategies to accelerate treatments for the underlying cause of cystic fibrosis for all people with CF, regardless of their mutations.

  12. CF Foundation Awards $2.76 Million for 11 COVID-19 Studies

    December 9, 2020

    Today, the Cystic Fibrosis Foundation awarded $2.76 million for 11 laboratory studies that will advance our understanding of the underlying factors that impact COVID-19 outcomes in people with cystic fibrosis. Ultimately, insights gained from this body of research may be used to improve future treatments.
More Posts View All Posts

Related Content

Follow Us On